عنوان الدراسة | الجهاز | رقم البروتوكول | الراعي | الحالة | موقع الدراسة |
---|---|---|---|---|---|
An open label, Phase IV Multicentric Single Arm Study to Assess the Safety and Efficacy of Croma Ophthalmic Solution Containing Sodium Cromoglycate (40 mg/ml) and Tetrahydrozoline Hydrochloride (0.5 mg/ml) in Subjects with Chronic Allergic Conjunctivitis | CROMA001 |
Jamjoom Pharmaceuticals |
مكتمل | King Khalid University Hospital (Riyadh) | |
An Open Label, Phase IV, Multi-Centric, Prospective, Single Arm Study to Assess the Safety and Efficacy of Fluca Eye Drops Containing Sodium Cromoglycate (20 mg/ml) and Fluorometholone (1 mg/ml) in Subjects with Chronic Allergic Conjunctivitis and Hay Fe | FLUCA001 |
Jamjoom Pharmaceuticals |
مكتمل | King Khalid University Hospital (Riyadh) | |
An Open Label, Phase IV, Multi-Centric, Prospective, Single Arm Study to Assess the Safety and Efficacy of Loxtra Eye Drops Containing Ofloxacin (3 mg), Prednisolone (2 mg) and Tetrahydrozoline Hydrochloride (0.4 mg) in Subjects with Bacterial Conjunctiv | LOX001 |
Jamjoom Pharmaceuticals |
مكتمل | King Khalid University Hospital (Riyadh) | |
A Phase IV Double-Blind Placebo-Controlled Randomized Clinical Trial Assessing the Effect of 2 month consumption of Vetal Laban Including Lactobacillus acidophilus NCFM on Functional Gastrointestinal Symptoms Among Subjects Fulfilling Rome III Criteria | IBS - 0920 |
Almarai |
مرفوض | King Fahad Medical City (Riyadh) | |
A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutati | D5160C00007 |
AstraZeneca |
منتهي | King Faisal Specialist Hospital and Research Center (Riyadh) | |
Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR)T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior The | D5160C00022 |
AstraZeneca |
مكتمل | King Fahad Specialist Hospital (Dammam) | |
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Determine The Efficacy And Safety Of Luspatercept (Ace-536) Versus Placebo In Adults Who Require Regular Red Blood Cell Transfusions Due To Beta -Thalassemia The “BELIEVE” | ACE-536-B-THAL-001 |
Celgene |
مكتمل | King Khalid University Hospital (Riyadh) | |
Randomized, two-way, two- period, single oral dose, open- label, crossover, bioequivalence study to compare Diclofenac Potassium powder for oral solution (50 mg diclofenac potassium) manufactured by Riyadh Pharma versus Catafast® powder for oral solutio | 42856 |
Saudi Ajal |
مكتمل | Saudi Ajal | |
A Prospective, Longitudinal, Multinational, Observational Study to Describe Patterns of Care and Outcomes of Men who are at High Risk for Poor Clinical Outcomes after Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men with | ONC-MA1001 |
Astellas |
مرفوض | ||
"A prospective, observational, non-randomized, European, multi-center registry, collecting REal-life information for the utilization of instantaneous wave-free ratio™ (iFR®) in Assessing coronary stenosis relevance in the Multi-vesseL disease patie |
2014-CV-00 |
Volcano |
مرفوض |